Fluorouracil
- Generic Name
- Fluorouracil
- Brand Names
- Actikerall, Carac, Efudex, Fluoroplex, Tolak
- Drug Type
- Small Molecule
- Chemical Formula
- C4H3FN2O2
- CAS Number
- 51-21-8
- Unique Ingredient Identifier
- U3P01618RT
- Background
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.
- Indication
For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.
- Associated Conditions
- Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis
- Associated Therapies
- -
NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer
- Conditions
- Pathologic Stage II Esophageal Adenocarcinoma AJCC v8Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8Clinical Stage II Esophageal Adenocarcinoma AJCC v8Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8Thoracic Esophagus AdenocarcinomaCervical Esophagus AdenocarcinomaGastroesophageal Junction AdenocarcinomaPathologic Stage IIA Esophageal Adenocarcinoma AJCC v8Pathologic Stage III Esophageal Adenocarcinoma AJCC v8Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8
- Interventions
- First Posted Date
- 2020-11-04
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT04615013
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 816
- Registration Number
- NCT04607421
- Locations
- 🇺🇸
LAC & USC Medical Center, Los Angeles, California, United States
🇺🇸Cedars- Sinai Medical Center, Los Angeles, California, United States
🇺🇸Investigational Drug Service, The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
Oncological Benefits of Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients With T3-4 Gastric Cancer Cyt-
- First Posted Date
- 2020-10-22
- Last Posted Date
- 2020-11-25
- Lead Sponsor
- St. Petersburg State Pavlov Medical University
- Target Recruit Count
- 304
- Registration Number
- NCT04595929
- Locations
- 🇷🇺
First Pavlov State Medical University of St. Petersburg, Saint-Petersburg, Russian Federation
Infusional Fluorouracil and Weekly Docetaxel for Gastric Cancer With Bone Marrow Involvement and DIC
- Conditions
- Interventions
- First Posted Date
- 2020-09-14
- Last Posted Date
- 2024-03-25
- Target Recruit Count
- 24
- Registration Number
- NCT04547153
- Locations
- 🇨🇳
Jian Xiao, Guangzhou, Guangdong, China
NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-09-07
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 60
- Registration Number
- NCT04539808
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines
- Conditions
- Advanced Colorectal CarcinomaMetastatic Digestive System CarcinomaStage IV Colorectal Cancer AJCC v8Advanced Gastric CarcinomaClinical Stage IV Gastric Cancer AJCC v8Advanced Gastroesophageal Junction AdenocarcinomaClinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Metastatic Gastroesophageal Junction AdenocarcinomaStage III Colorectal Cancer AJCC v8
- Interventions
- First Posted Date
- 2020-09-02
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 10
- Registration Number
- NCT04535401
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland, United States
🇺🇸National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Short-Course Chemoradiotherapy Followed by Chemotherapy for the Treatment of Resectable Gastric Adenocarcinoma
- Conditions
- Clinical Stage IVA Gastric Cancer AJCC v8Gastric AdenocarcinomaPostneoadjuvant Therapy Stage I Gastric Cancer AJCC v8Clinical Stage III Gastric Cancer AJCC v8Pathologic Stage IIIC Gastric Cancer AJCC v8Postneoadjuvant Therapy Stage III Gastric Cancer AJCC v8Pathologic Stage IB Gastric Cancer AJCC v8Pathologic Stage IIB Gastric Cancer AJCC v8Pathologic Stage IIIB Gastric Cancer AJCC v8Postneoadjuvant Therapy Stage II Gastric Cancer AJCC v8
- Interventions
- First Posted Date
- 2020-08-24
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT04523818
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer
- Conditions
- Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8Localized Gastroesophageal Junction AdenocarcinomaLocally Advanced Gastroesophageal Junction AdenocarcinomaPathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
- Interventions
- First Posted Date
- 2020-08-21
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 16
- Registration Number
- NCT04522336
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Induction Chemotherapy in Locally Advanced Hypopharyngeal Carcinoma: a Randomised Phase 3 Trial
- Conditions
- Interventions
- First Posted Date
- 2020-08-06
- Last Posted Date
- 2020-08-06
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 160
- Registration Number
- NCT04502641
- Locations
- 🇨🇳
The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
Immunoscore as Decision Guidance for Adjuvant Chemotherapy in Colon Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-07-27
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Johannes Laengle, MD, PhD
- Target Recruit Count
- 1638
- Registration Number
- NCT04488159
- Locations
- 🇦🇹
Medical University of Vienna, Vienna, Austria
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.